Id |
Subject |
Object |
Predicate |
Lexical cue |
T124 |
0-72 |
Sentence |
denotes |
Furthermore, PASylation can serve as a linker to join two peptides [69]. |
T125 |
73-197 |
Sentence |
denotes |
This is of particular interest if both entities act synergistically, for example, GLP-1 and GIP [70] or Tα1 and GM-CSF [71]. |
T126 |
198-463 |
Sentence |
denotes |
Alternatively, the biologically active protein/peptide can be linked via the PAS sequence to a targeting domain such as the arginylglycylaspartic acid peptide RGD peptide which binds to integrins αVβ3 and αVβ5 in order to enhance tumor penetration and accumulation. |
T127 |
464-621 |
Sentence |
denotes |
In fact, fusion of the short-acting Tα1 with the tumor-targeting iRGD peptide using a Gly4 linker has recently demonstrated enhanced antitumor activity [50]. |
T128 |
622-794 |
Sentence |
denotes |
In contrast to synthetic PEG linkers, which are commonly used for bioconjugations, the recombinant PAS sequence exhibits a precisely defined size and is biodegradable [72]. |
T129 |
795-974 |
Sentence |
denotes |
The PAS polypeptide itself is stable in blood plasma but quickly degraded by intracellular enzymes, thus avoiding organ accumulation [31], a well-known effect for PEGylation [73]. |
T130 |
975-1292 |
Sentence |
denotes |
Moreover, PAS sequences are non-immunogenic in animals [31,74] and offer a one-step production of PASylated peptides in various commercially scalable expression systems including bacteria, yeasts, or mammalian cells [35,48], which would even allow the preparation of peptides carrying posttranslational modifications. |